I wouldn't call it a pivot.
In fact many here have been speculating that Imugene might aquire a CD19 CAR company for a while now. I had my money on Arovella given the current collaboration and the fact that PH stepped down as their Chairman.
But it makes sense to aquire or license a CD19 CAR technology that is much closer to commercialisation, such as this one.
Orphan designation and fast track designation. Incredible.
YF did mention that they plan on starting a cellular onCARlytics trial next year. Maybe it will be with this product?
I wouldn't call it a pivot.In fact many here have been...
-
- There are more pages in this discussion • 457 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $379.2M | |||
| Open | High | Low | Value | Volume |
| 5.2¢ | 5.2¢ | 5.0¢ | $1.098M | 21.50M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 97 | 7481668 | 5.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.1¢ | 1703097 | 4 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |